Clinical trial NCT04221529: Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Official title: Single-Arm Phase II-Study in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) With Poor Performance Status Receiving Atezolizumab-Carboplatin-Etoposide
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: SCLC, Extensive Stage
Keywords: Atezolizumab
Lead sponsor: AIO-Studien-gGmbH
Sponsor class: OTHER
Collaborators: name: Hoffmann-La Roche
First posted: 2020-01-09
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver and brain.

Compared with non-small-cell lung cancer (NSCLC) SCLC has a unique natural history with a shorter doubling time, higher growth fraction, earlier development of widespread metastases, and uniform initial response to chemo- or radiotherapy.

The combination of cis- or carboplatin and etoposide is the standard of care in the first-line treatment of stage IV (extensive-disease) SCLC (ED-SCLC). Despite response rates of 50-80%, most patients relapse within six months and the median survival time is less than 10 months. Between 14 and 23% of SCLC patients develop brain metastases.

New cytotoxic agents as well as targeted therapies have not been able to show any improvement of survival in this group of patients.

Early phase trials of PD 1/PD L1-blocking immunotherapeutic agents in patients with recurrent or ED SCLC have shown promising response rates and good tolerability. Immunotherapy may also contribute to the efficacy of systemic treatment by maintaining initial responses to chemotherapy. A double-blind, placebo-controlled phase 3 trial indicates that the addition of atezolizumab to standard chemotherapy significantly improves overall survival and progression-free survival compared with chemotherapy alone in treatment-naïve patients with ED-SCLC who are in good general condition (ECOG 0 or 1). However, about one in three SCLC patients has a poor performance status (ECOG≥2), which is associated with even shorter survival times of under eight months. At present, there is little information regarding the feasibility, safety and efficacy of adding atezolizumab to standard chemotherapy for this considerable fraction of patients.

The investigators expect, that atezolizumab in addition to chemotherapy is feasible in patients with stage IV SCLC and reduced performance status and therefore crucial efficacy data can be acquired in this trial to evaluate a putative Phase III transition in this particular patient population.


Eligibility criteria: Inclusion Criteria:

* Written informed consent including participation in translational research obtained from the subject prior to performing any protocol-related procedures, including screening evaluations that are not SOC.
* ECOG 2
* At least one measurable tumor lesion (according to RECIST1.1)
* Histologically confirmed small cell lung cancer (SCLC)
* Stage IV disease (according to UICC8)
* No active autoimmune disease
* Adequate organ function defined as:

  * neutrophil count \> 1.5 x 109/L
  * thrombocytes ≥ 100 x 109/L
  * hemoglobin ≥ 9 g/dL
  * INR ≤ 1.4 or aPTT ≤ 40 sec during the last 7 days before therapy \[Subjects under therapeutic anticoagulation are permitted.\]
  * bilirubin \< 1.5 x ULN
  * AST (SGOT)/ALT (SGPT) \< 3 x institutional ULN (\< 5 x ULN in case of liver metastases)
  * creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 45 mL/min
* Availability of tumor tissue/block
* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the first dose of IMP.
* Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. \[WOCBP should use an adequate method to avoid pregnancy for 6 months after the last dose of IMP.\]
* Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving IMP and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 6 months after the last dose of IMP. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men who are azoospermic do not require contraception.
* Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up.

Exclusion Criteria:

* Any preceding systemic anticancer therapy for stage IV SCLC. \[Up to one full-cycle-dosing of carboplatin+etoposide chemotherapy within the context of SOC is permitted prior to study treatment.\] (Note: Prior treatment for limited stage disease allowed).
* Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lives of previously used trial medication, whichever is longer
* Prior therapy with an anti-Programmed cell death protein 1 (anti-PD-1), anti-Programmed cell death-ligand 1 (anti-PD-L1), anti-Programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor \[TNFR\] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
* Previous treatment in the present study (does not include screening failure).
* Symptomatic CNS metastases. \[Patients with asymptomatic brain metastases may be included.\]
* Major surgery ≤ 28 days before first dose of study treatment
* Any uncontrolled systemic disease, condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, including but not limited to:

  1. known active HBV, HCV or HIV infection \[Patients who are HIV-positive are allowed in the trial, so long as they are stable on anti-retroviral therapy, have a CD4 count ≥ 200 cells/μL, and have an undetectable viral load at the time of screening.\]
  2. active tuberculosis
  3. any other active infection requiring systemic therapy
  4. history of allogeneic tissue/solid organ transplant
  5. diagnosis of immunodeficiency or patient is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of IMP
  6. other active malignancy requiring treatment
  7. clinically significant or symptomatic cardiovascular/cerebrovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrolment
* Female subjects who are pregnant, breast-feeding or male/female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year).
* Known hypersensitivity to carboplatin, etoposide or atezolizumab or any of the constituents of the product.
* Medication that is known to interfere with any of the agents applied in the trial.
* Any condition or disease which might interfere with the subject's ability to comply with the study procedures (e.g., dementia).
* Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities \[§ 40 Abs. 1 S. 3 Nr. 4 AMG\].
* Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \[§ 40 Abs. 1 S. 3 Nr. 3a AMG\].

Primary outcomes:
measure: Overall survival (OS)
timeFrame: Measured from first dose of experimental IMP (or first dose of chemotherapy, whichever occurs first) through study completion, an average of one year.
Secondary outcomes:
measure: Objective response rate (ORR) (RECIST 1.1)
timeFrame: Starting from Screening up to an average of one year.
measure: Progression-free suvival (PFS)
timeFrame: Starting from Screening up to an average of one year.
measure: Incidence of Treatment-Emergent adverse events, serious adverse events and laboratory abnormalities leading to treatment discontinuation
timeFrame: Starting from Screening up to an average of one year.
measure: Quality of life (EORTC-QLQ-C30)
timeFrame: Starting from Screening up to an average of one year.
measure: Quality of life (PRO-CTCAE)
timeFrame: Starting from Screening up to an average of one year.
Other outcomes:
Locations:
city: Klagenfurt
country: Austria
facility: Klinikum Klagenfurt
city: Krems
country: Austria
facility: Universitätsklinikum Krems
city: Wien
country: Austria
facility: Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie c/o Wilhelminenspital der Stadt Wien
city: Bochum
country: Germany
facility: St. Josef Hospital
city: Esslingen
country: Germany
facility: Klinikum Esslingen GmbH
city: Freiburg
country: Germany
facility: Universitätsklinikum Freiburg
city: Georgsmarienhütte
country: Germany
facility: Niels-Stensen-Kliniken
city: Großhansdorf
country: Germany
facility: LungenClinic Grosshansdorf GmbH
city: Halle
country: Germany
facility: Krankenhaus Martha-Maria Halle-Dölau
city: Hamburg
country: Germany
facility: Asklepios Klinik Altona
city: Heidelberg
country: Germany
facility: Universität Heidelberg
city: Löwenstein
country: Germany
facility: Klinikum Löwenstein gGmbH
city: Marburg
country: Germany
facility: Universitätsklinikum Gießen und Marburg GmbH
city: Minden
country: Germany
facility: Johannes Wesling Klinikum
city: München
country: Germany
facility: Klinikum der Universität München
city: Paderborn
country: Germany
facility: Brüderkrankenhaus St. Josef
city: Wangen Im Allgäu
country: Germany
facility: Fachkliniken Wangen
city: Wiesbaden
country: Germany
facility: Helios Dr. Horst Schmidt Kliniken Wiesbaden
city: Wuppertal
country: Germany
facility: Helios Universitätsklinikum
Study officials:
affiliation: LungenClinic Grosshansdorf
name: Martin Reck, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: